SCHEMBL7540150

SCHEMBL7540150

COc1ccc(NS(=O)(=O)c2ccc(S(=O)(=O)c3ccccc3)c(C#N)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.58
GAA P10253 3/20 0.55
ALDH1A1 P00352 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
PGR P06401 6/20 0.55
PLAU P00749 2/20 0.53
LMNA P02545 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
HTT P42858 1/20 0.53
PKM P14618 1/20 0.51
POLB P06746 1/20 0.49
CYP19A1 P11511 1/20 0.49
MAPK1 P28482 1/20 0.49
ABCC9 O60706 1/20 0.48
ABCC8 Q09428 1/20 0.48
KCNJ11 Q14654 1/20 0.48
KCNJ8 Q15842 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7534915 0.87 KDM4E (0.52) MAPTGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL7533321 0.87 LMNA (0.60) MAPTALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL7537206 0.84 MAPT (0.53) MAPTALDH1A1PGRLMNAMEN1
SCHEMBL7533132 0.84 LMNA (0.50) MAPTALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL7537146 0.84 CA12 (0.48) MAPTGAAALDH1A1SMN1; SMN2LMNA
SCHEMBL6677124 0.80 MAPT (0.61) MAPTGAAALDH1A1SMN1; SMN2PGR
SCHEMBL6675705 0.80 MAPT (0.61) MAPTGAAALDH1A1PGRPLAU
SCHEMBL6674281 0.80 MAPT (0.61) MAPTGAAALDH1A1PGRPLAU
SCHEMBL29031235 0.78 PGR (0.85) MAPTGAAALDH1A1SMN1; SMN2PGR
SCHEMBL4662975 0.77 PGR (0.82) MAPTGAAALDH1A1SMN1; SMN2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 MAPT 2283/4885GAA 1364/4885ALDH1A1 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.